胆管癌靶向新药培美替尼的临床研究效果和副作用是什么？

Pemetinib, a small molecule kinase inhibitor targeting FGFR1, 2, and 3, is a selective fibroblast growth factor receptor (FGFR) inhibitor that received accelerated approval from the FDA on April 17, 2020, for previously treated patients with locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements.

So, what is the clinical research effect of the new cholangiocarcinoma-targeted drug pemetinib?

The FIGHT-202 study trial was conducted in patients with previously treated locally advanced or metastatic cholangiocarcinoma. All patients received oral pemetinib 13.5 mg once daily in a 21-day cycle (2 weeks on, 1 week off) until radiographic disease progression or intolerable toxicity. The results showed that among patients carrying FGFR2 fusions or rearrangements, with a median follow-up of 15 months, the median duration of response (DoR) was 9.1 months (secondary endpoint), and the overall response rate (ORR) of pemetinib monotherapy was 36% (primary endpoint).

So, what are the side effects of pemetinib?

Clinical trials have shown that pemetinib is generally well tolerated. Constipation, taste changes, vomiting, loss of appetite, stomach pain, aphtha, diarrhea, nausea, weight loss, dry mouth and/or dry skin; decreased urine output; rapid heartbeat; onychomycosis, joint pain, painful urination, hair loss, headache, fatigue, swelling and pain of limbs or joints, etc. are some of the more common side effects of pemetinib. It is recommended that patients follow the doctor's instructions and take medication, and only symptomatic treatment can achieve the effect. Pemetinib has proven to have selective pharmacological activity against cancer cells with FGFR alterations and is the world's first targeted therapy for cholangiocarcinoma. However, it is not recommended for pregnant women to use pemetinib.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: